our adjusted quarterly earnings per share of $num-one increased num-two% from year-four, reflecting sales growth partially offset by higher interest charges resulting from the wright acquisition as well as an overall disciplined ramp-up in operating costs.
these trends give us confidence in achieving our guidance of num-one% to num-two% full year organic sales growth compared to year-four, which is equivalent to num-three% to num-four% organic versus year-five, despite one less selling day.
based on our first quarter performance and the current operating environment, we continue to expect year-six organic net sales growth to be in the range of num-one% to num-two%.
based on our first quarter performance and including consideration of our improved full year wright medical sales impact, disciplined cost management, and continued positive recovery outlook, we now expect adjusted net earnings per diluted share to be in the range of $num-one to $num-two.
for the quarter, us organic sales increased by num-one%, reflecting the continuing slowdown in elective procedures as a result of the pandemic, somewhat offset by strong demand for mako, medical products, and neurovascular products.
if foreign currency exchange rates hold near current levels, we expect net sales in the full year will be positively impacted by approximately num-one%.